The data displays the research and development expenses of the United States biotech industry - represented by public biotech companies only from 2012 to 2014, sorted by (metropolitan) region. In New England, the R&D expense incurred by such companies came to some 5.3 billion USD in 2013.
San Francisco Bay Area | 4664 | 5081 | 6883 |
New England | 4172 | 5253 | 6487 |
Los Angeles/Orange County | 3649 | 4375 | 4965 |
New Jersey | 2030 | 2712 | 2973 |
New York State | 981 | 1224 | 1863 |
San Diego | 1301 | 1546 | 1677 |
Pacific Northwest | 608 | 530 | 858 |
Mid-Atlantic | 543 | 739 | 808 |
Pennsylvania/Delaware Valley | 404 | 504 | 575 |
North Carolina | 284 | 369 | 489 |
Southeast | 172 | 202 | 239 |
Texas | 154 | 174 | 237 |
Colorado | 127 | 151 | 226 |
Midwest | 220 | 197 | 193 |
Utah | 59 | 61 | 85 |
Other | 131 | 167 | 273 |